MarketCapExport financials
iBio (IBIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
iBio Balance Sheet 2026-2010 | IBIO
Brief overview of iBio's financial position
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets finished at $23.2 million versus $147 million initially, losing -84.2%. The balance sheet contracted.
Asset growth of -84.2% was close to the -78.4% change in liabilities, leaving the funding profile broadly stable.
Internal capital represents 64.2% of the balance sheet, previously 73.9%. This is a strong capital position.
Cash exceeds interest-bearing debt, producing net debt of -$5.9 million. The balance sheet therefore carries a net cash position.
Cash represents 37% of assets versus 52.7% initially, showing how the immediate liquidity reserve changed.
The accumulated result is -$332.2 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
iBio retains a reasonably healthy balance sheet structure, which still needs support from earnings and cash flow.
Annual Balance Sheet iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-54.2 M | -5.89 M | -13.7 M | -3.56 M | -22.6 M | -45.6 M | -54.5 M | 20.5 M | 9.15 M | 17.2 M | 2.42 M | -9.49 M | -3.59 M | -4.41 M | -5.62 M | -2.84 M | - |
Long Term Debt |
1.65 M | 2.2 M | 53 K | 351 K | 30 K | 31.8 M | 339 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
546 K | 490 K | 436 K | 389 K | 91 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 32.3 M | 24.7 M | 24.9 M | 25.1 M | 25.3 M | - | - | - | - | - | - |
Total Current Liabilities |
11.7 M | 6.11 M | 3.84 M | 22.1 M | 30.4 M | 6.64 M | 5.24 M | 3.46 M | 2.04 M | 2.01 M | 2.29 M | - | 395 K | 4.29 M | 3.6 M | - | - |
Total Liabilities |
13.4 M | 8.3 M | 7.41 M | 25.8 M | 35.9 M | 38.4 M | 37.6 M | 28.1 M | 26.9 M | 27.1 M | 27.6 M | 1.26 M | 395 K | 4.29 M | 3.6 M | 7.14 M | - |
Deferred Revenue |
1.15 M | 1.2 M | 200 K | - | 100 K | 423 K | 1.81 M | 1.28 M | - | 157 K | 24 K | - | - | - | - | - | - |
Retained Earnings |
-365 M | -332 M | -314 M | -289 M | -224 M | -174 M | -150 M | -106 M | -88.2 M | -72.1 M | -57.6 M | -47.8 M | -41.2 M | -37.5 M | -31.3 M | -25.7 M | - |
Total Assets |
99.1 M | 23.2 M | 28.7 M | 41.2 M | 99.4 M | 147 M | 94.2 M | 30.6 M | 43.1 M | 36 M | 51.6 M | 12.5 M | 6.49 M | 9.35 M | 9.76 M | 7.34 M | - |
Cash and Cash Equivalents |
56.4 M | 8.58 M | 14.2 M | 4.3 M | 22.7 M | 77.4 M | 55.1 M | 4.42 M | 4.42 M | 8.09 M | 8.09 M | 9.49 M | 3.59 M | 4.41 M | 5.62 M | 2.84 M | 910 K |
Book Value |
85.7 M | 14.9 M | 21.3 M | 15.4 M | 63.5 M | 109 M | 56.6 M | 2.46 M | 16.2 M | 8.92 M | 24 M | 11.2 M | 6.1 M | 5.07 M | 6.17 M | 197 K | - |
Total Shareholders Equity |
85.7 M | 14.9 M | 21.3 M | 15.4 M | 63.5 M | 109 M | 56.6 M | 2.46 M | 16.2 M | 8.91 M | 9.94 M | 11.2 M | 6.1 M | 5.07 M | 6.17 M | 196 K | 1.08 M |
All numbers in USD currency
Quarterly Balance Sheet iBio
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.2 M | 1.79 M | 1.93 M | 2.07 M | 1.93 M | 2.07 M | 2.2 M | 2.32 M | 2.45 M | 2.2 M | 53 K | 130 K | 205 K | 53 K | 351 K | 422 K | 490 K | 576 K | 3.51 M | 41 K | 51 K | 31.7 M | 31.8 M | 31.8 M | 31.8 M | 31.9 M | 32 M | 32 M | 32.2 M | 32.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.3 M | 8.3 M | 7.83 M | 8.12 M | 7.83 M | 8.12 M | 8.3 M | 7.72 M | 7.8 M | 6.76 M | 7.41 M | 25.3 M | 24.8 M | 24.5 M | 25.8 M | 27 M | 33 M | 36.2 M | 35.9 M | 36 M | 35.8 M | 43.2 M | 38.4 M | 38.4 M | 38.1 M | 37.2 M | 37.6 M | 37.6 M | 36.9 M | 37.1 M | 28.1 M | 28.1 M | 29.2 M | 29.9 M | 26.9 M | 26.9 M | 27 M | 27.1 M | 27.1 M | 27.1 M | 27 M | 27.4 M | 27.6 M | 27.6 M | 1.54 M | 1.56 M | 1.26 M | 1.26 M | 1.48 M | 1.22 M | 395 K | 395 K | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
200 K | 1.15 M | 1.15 M | 1.15 M | 1.15 M | 1.15 M | 1.2 M | 600 K | 600 K | 400 K | 200 K | 175 K | - | - | - | - | 88 K | 161 K | 100 K | 8 K | 60 K | 94 K | 423 K | 423 K | 1.23 M | 1.37 M | 1.81 M | 1.81 M | 3.03 M | 2.89 M | 1.28 M | 1.28 M | 2.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-332 M | -355 M | -347 M | -338 M | -347 M | -338 M | -332 M | -327 M | -322 M | -318 M | -314 M | -306 M | -303 M | -295 M | -289 M | -283 M | -276 M | -242 M | -224 M | -207 M | -194 M | -183 M | -174 M | -174 M | -166 M | -158 M | -150 M | -150 M | -136 M | -110 M | -106 M | -106 M | -97.1 M | -92.6 M | -88.2 M | -88.2 M | -79.8 M | -75.9 M | -72.1 M | -72.1 M | -63.9 M | -60.7 M | -57.6 M | -57.6 M | -51.9 M | -49.6 M | -47.8 M | -47.8 M | -44.3 M | -42.6 M | -41.2 M | -41.2 M | -38.8 M | -37.2 M | -37.5 M | -37.5 M | -34.5 M | -33.4 M | -31.3 M | -31.3 M | -26.9 M | -25.3 M | -25.7 M | -25.7 M |
Total Assets |
23.2 M | 85.8 M | 64.4 M | 64.2 M | 64.4 M | 64.2 M | 23.2 M | 19.1 M | 21.7 M | 24.5 M | 28.7 M | 50.2 M | 34 M | 37.7 M | 41.2 M | 44.4 M | 51.8 M | 84.6 M | 99.4 M | 115 M | 126 M | 144 M | 147 M | 147 M | 145 M | 117 M | 145 M | 117 M | 36.4 M | 35.2 M | 36.4 M | 35.2 M | 40.3 M | 42.9 M | 40.3 M | 42.9 M | 34.8 M | 33.4 M | 34.8 M | 33.4 M | 44.2 M | 48.1 M | 44.2 M | 48.1 M | 9.42 M | 11.4 M | 9.42 M | 11.4 M | 11 M | 6.66 M | 6.49 M | 6.49 M | 9.62 M | 7.34 M | 9.35 M | 9.35 M | 6.81 M | 7.99 M | 9.76 M | 9.76 M | 5.02 M | 5.58 M | 7.34 M | 7.34 M |
Cash and Cash Equivalents |
14.4 M | 47.6 M | 28.7 M | 28.1 M | 28.7 M | 28.1 M | 8.58 M | 4.96 M | 7.24 M | 11.3 M | 14.2 M | 6.43 M | 4.06 M | 4.76 M | 4.3 M | 9.78 M | 3.95 M | 15.9 M | 22.7 M | 39.7 M | 45.1 M | 62.8 M | 77.4 M | 77.4 M | 91.3 M | 77.5 M | 55.1 M | 77.5 M | 3.64 M | 2.1 M | 3.64 M | 2.1 M | 13.4 M | 8.16 M | 13.4 M | 16 M | 7.31 M | 5.92 M | 7.31 M | 5.92 M | 16.3 M | 20.1 M | 16.3 M | 20.1 M | 6.73 M | 8.38 M | 6.73 M | 8.38 M | 7.36 M | 3.49 M | 7.36 M | 3.49 M | 5.68 M | 3.44 M | 5.68 M | 3.44 M | 2.82 M | 4.28 M | 2.82 M | 4.28 M | 623 K | 1.52 M | 623 K | 1.52 M |
Book Value |
14.9 M | 77.5 M | 56.6 M | 56 M | 56.6 M | 56 M | 14.9 M | 11.4 M | 13.9 M | 17.8 M | 21.3 M | 24.9 M | 9.2 M | 13.2 M | 15.4 M | 17.4 M | 18.8 M | 48.4 M | 63.5 M | 79.4 M | 90.6 M | 101 M | 109 M | 109 M | 107 M | 80 M | 108 M | 79.7 M | -520 K | -1.94 M | 8.26 M | 7.04 M | 11.1 M | 13 M | 13.4 M | 16 M | 7.81 M | 6.29 M | 7.74 M | 6.34 M | 17.1 M | 20.7 M | 16.6 M | 20.5 M | 7.88 M | 9.81 M | 8.15 M | 10.1 M | 9.57 M | 5.44 M | 6.1 M | 6.1 M | 9.62 M | 7.34 M | 9.35 M | 9.35 M | 6.81 M | 7.99 M | 9.76 M | 9.76 M | 5.02 M | 5.58 M | 7.34 M | 7.34 M |
Total Shareholders Equity |
21.3 M | 77.5 M | 56.6 M | 56 M | 56.6 M | 56 M | 14.9 M | 11.4 M | 13.9 M | 17.8 M | 21.3 M | 24.9 M | 9.2 M | 13.2 M | 15.4 M | 17.4 M | 18.8 M | 48.4 M | 63.5 M | 79.4 M | 90.6 M | 101 M | 109 M | 109 M | 107 M | 80.1 M | 56.6 M | 56.6 M | -511 K | -1.93 M | 2.46 M | 2.46 M | 11.1 M | 13 M | 16.2 M | 16.2 M | 7.81 M | 6.29 M | 8.91 M | 8.91 M | 4.15 M | 7.14 M | 9.94 M | 9.94 M | 7.88 M | 9.81 M | 11.2 M | 11.2 M | 9.57 M | 5.44 M | 6.1 M | 6.1 M | 7.95 M | 5.68 M | 5.07 M | 5.07 M | 3.72 M | 4.57 M | 6.17 M | 6.17 M | 305 K | 886 K | 196 K | 197 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of iBio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
Russia
Schweiz
Britain
